Renfrew Group have been working with UCL and manufacturers as well as patient and clinical groups on the design of a workstation for a highly innovative cryopreservable bio-artificial liver for the treatment of patients with liver failure. The machine, the first of its kind, will buy time for a patient’s liver to improve or if damage to the liver is irreversible, buy time until liver transplantation can be arranged.
The program which is working toward first ‘in man’ trials, is led by Clare Selden PhD, funded by a National Institute for Health Research (NIHR), for this research project. Professor of Experimental Hepatology of The Liver Group at University College Medical School, Royal Free Hospital Campus. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR www.nihr.ac.uk or the Department of Health and Social Care.